Patents by Inventor Robert W. Gerwien
Robert W. Gerwien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11340236Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: GrantFiled: September 6, 2019Date of Patent: May 24, 2022Assignees: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Publication number: 20210164976Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: February 4, 2021Publication date: June 3, 2021Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 10928393Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: October 25, 2018Date of Patent: February 23, 2021Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20200335220Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: July 7, 2020Publication date: October 22, 2020Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10741290Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 10, 2019Date of Patent: August 11, 2020Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20190391162Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: ApplicationFiled: September 6, 2019Publication date: December 26, 2019Applicants: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Patent number: 10408845Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: GrantFiled: December 6, 2016Date of Patent: September 10, 2019Assignees: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Publication number: 20190237197Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10303844Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: December 20, 2016Date of Patent: May 28, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20190049444Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: October 25, 2018Publication date: February 14, 2019Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20180018442Abstract: Provided are methods, algorithms, nomograms, and computer/software systems that can be used to accurately determine the risk of developing heart failure within a specific time period in a subject not diagnosed or presenting with heart failure. Also provided are methods, algorithms, nomograms, computer/software systems for selecting a treatment for a subject and determining the efficacy of a treatment for reducing the risk of heart failure in a subject.Type: ApplicationFiled: October 4, 2017Publication date: January 18, 2018Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20170316153Abstract: A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbA1c; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.Type: ApplicationFiled: July 18, 2017Publication date: November 2, 2017Inventors: Michael P. McKenna, Michael Rowe, Edward J. Moler, JR., Robert W. Gerwien
-
Patent number: 9740819Abstract: A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.Type: GrantFiled: October 28, 2010Date of Patent: August 22, 2017Assignee: TRUE HEALTH IP LLCInventors: Michael P. McKenna, Michael Rowe, Edward J. Moler, Jr., Robert W. Gerwien
-
Publication number: 20170169179Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: December 20, 2016Publication date: June 15, 2017Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20170146552Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: ApplicationFiled: December 6, 2016Publication date: May 25, 2017Applicants: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Publication number: 20170122942Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: January 18, 2017Publication date: May 4, 2017Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 9551708Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: June 9, 2014Date of Patent: January 24, 2017Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20150199491Abstract: Provided are methods, algorithms, nomograms, and computer/software systems that can be used to accurately determine the risk of developing heart failure within a specific time period in a subject not diagnosed or presenting with heart failure. Also provided are methods, algorithms, nomograms, computer/software systems for selecting a treatment for a subject and determining the efficacy of a treatment for reducing the risk of heart failure in a subject.Type: ApplicationFiled: January 9, 2015Publication date: July 16, 2015Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20140286944Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 8748110Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: July 18, 2012Date of Patent: June 10, 2014Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien